Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in
The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be ful
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh